Biographical Sketch
Paul J. Beisswenger M.D.
212 Vail, DMS
Lab: (603) 650-1808
Office: 650-8630
paul.j.beisswenger@hitchcock.org
My research program is focused on determining the role of enzymatic control of nonenzymatic glycation in the cellular and tissue damage associated with diabetes. My focus is on factors that regulate toxic dicarbonyl compounds, and their resultant Advanced Glycation Endproducts (AGEs). These are produced in excess in diabetes and play an important role in the development of diabetic complications. Our laboratory is also at the very forefront of research in the new area of enzymatic deblycation. We currently combine the following studies of human populations with powerful analytic laboratory techniques to address some the important outstanding questions regarding diabetic complications.
- 1. The Role of —dicarbonyl metabolism and enzymatic deglycation in susceptibility to Diabetic Nephropathy
- 2. The Effect of scavenging guanidine compounds on dicarbonyl, AGE production, and diabetic complications
- 3. The Effect of blycemic fluctuations on Reactive alpha-dicarbonyls, tissue glycation, and diabetic complications
My overall objectives are to create a research program which will span the hitherto neglected interface between clinical and basic science and provide a fertile training ground for new scientific investigators.